NEWS
Chimerix Announces Updated Phase 2 Response Assessment of Dordaviprone in Recurrent H3 K27M Glioma at the 2024 SNO Meeting
Chimerix (NASDAQ: CMRX) announced updated Phase 2 response assessment results for dordaviprone in treating recurrent H3 K27M-mutant diffuse midline glioma. Using the new RANO 2.0 criteria, the treatment showed a 28.0% overall response rate, with a median time to response of 4.6 months and a median duration of response of 10.4 months. The company plans to include these updated results in their upcoming New Drug Application to Australian regulators. The findings will be presented at the 2024 Society for Neuro-Oncology Annual Meeting in Houston, along with additional pipeline presentations.
免責聲明：社區由Moomoo Technologies Inc.提供，僅用於教育目的。
更多信息
評論
登錄發表評論
